Investigating Chemokine-Matrix Networks in Breast Cancer: Tenascin-C Sets the Tone for CCL2

Bidirectional dialogue between cellular and non-cellular components of the tumor microenvironment (TME) drives cancer survival. In the extracellular space, combinations of matrix molecules and soluble mediators provide external cues that dictate the behavior of TME resident cells. Often studied in isolation, integrated cues from complex tissue microenvironments likely function more cohesively. Here, we study the interplay between the matrix molecule tenascin-C (TNC) and chemokine CCL2, both elevated in and associated with the progression of breast cancer and playing key roles in myeloid immune responses. We uncover a correlation between TNC/CCL2 tissue levels in HER2+ breast cancer and examine the physical and functional interactions of these molecules in a murine disease model with tunable TNC levels and in in vitro cellular and cell-free models. TNC supported sustained CCL2 synthesis, with chemokine binding to TNC via two distinct domains. TNC dominated the behavior of tumor-resident myeloid cells; CCL2 did not impact macrophage survival/activation whilst TNC facilitated an immune suppressive macrophage phenotype that was not dependent on or altered by CCL2 co-expression. Together, these data map new binding partners within the TME and demonstrate that whilst the matrix exerts transcriptional control over the chemokine, each plays a distinct role in subverting anti-tumoral immunity.

[1]  Mario C. Benn,et al.  Infiltrating CD8+ T cells and M2 macrophages are retained in tumor matrix tracks enriched in low tension fibronectin fibers. , 2023, Matrix biology : journal of the International Society for Matrix Biology.

[2]  M. Mörgelin,et al.  Modulating tenascin-C functions by targeting the MAtrix REgulating MOtif, "MAREMO". , 2022, Matrix biology : journal of the International Society for Matrix Biology.

[3]  Tao Liu,et al.  Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy? , 2021, Frontiers in Cell and Developmental Biology.

[4]  Wei Yu,et al.  CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment , 2021, Frontiers in Oncology.

[5]  N. Paul,et al.  Tenascin‐C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression , 2021, EMBO molecular medicine.

[6]  Y. Shyr,et al.  Expression of CCL2/CCR2 signaling proteins in breast carcinoma cells is associated with invasive progression , 2021, Scientific Reports.

[7]  A. Luster,et al.  Chemokines and the immune response to cancer. , 2021, Immunity.

[8]  R. Schwartz,et al.  Generation of Transgenic Mice that Conditionally Overexpress Tenascin-C , 2021, Frontiers in Immunology.

[9]  C. Deligne,et al.  Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies? , 2021, Frontiers in Oncology.

[10]  I. Baranowska-Bosiacka,et al.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4 , 2020, International journal of molecular sciences.

[11]  Katarzyna Rolle,et al.  Down-regulation of tenascin-C inhibits breast cancer cells development by cell growth, migration, and adhesion impairment , 2020, PloS one.

[12]  N. Paul,et al.  Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma , 2020, Cancer Immunology Research.

[13]  K. Midwood,et al.  Alternative splicing controls cell lineage-specific responses to endogenous innate immune triggers within the extracellular matrix. , 2020, Matrix biology : journal of the International Society for Matrix Biology.

[14]  D. Dyer Understanding the mechanisms that facilitate specificity, not redundancy, of chemokine‐mediated leukocyte recruitment , 2020, Immunology.

[15]  N. Paul,et al.  Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype , 2020, Cancer Immunology Research.

[16]  K. Midwood,et al.  More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis , 2019, Front. Immunol..

[17]  Xiaoping Zhou,et al.  Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer , 2019, Cancer science.

[18]  G. Christofori,et al.  Tenascin-C increases lung metastasis by impacting blood vessel invasions. , 2019, Matrix biology : journal of the International Society for Matrix Biology.

[19]  H. Kettenmann,et al.  Tenascin C regulates multiple microglial functions involving TLR4 signaling and HDAC1 , 2019, Brain, Behavior, and Immunity.

[20]  V. Weaver,et al.  The Extracellular Matrix Modulates the Metastatic Journey. , 2019, Developmental cell.

[21]  K. Hu,et al.  CCL2/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages , 2019, Front. Oncol..

[22]  E. Go,et al.  Determinants of Tenascin-C and HIV-1 envelope binding and neutralization , 2019, Mucosal Immunology.

[23]  A. Sato,et al.  Tenascin-C accelerates adverse ventricular remodelling after myocardial infarction by modulating macrophage polarization , 2018, Cardiovascular research.

[24]  M. Carcangiu,et al.  HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy , 2018, Oncoimmunology.

[25]  M. Heikenwalder,et al.  CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis , 2018, Molecular Cancer Research.

[26]  T. Yoshimura The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? , 2018, Cellular & Molecular Immunology.

[27]  Hongyu Chen,et al.  Chronic psychological stress promotes lung metastatic colonization of circulating breast cancer cells by decorating a pre‐metastatic niche through activating β‐adrenergic signaling , 2018, The Journal of pathology.

[28]  C. Deligne,et al.  How to detect and purify tenascin-C. , 2018, Methods in cell biology.

[29]  A. Prats,et al.  Local production of tenascin-C acts as a trigger for monocyte/macrophage recruitment that provokes cardiac dysfunction , 2018, Cardiovascular research.

[30]  D. Grall,et al.  Counterbalancing anti-adhesive effects of Tenascin-C through fibronectin expression in endothelial cells , 2017, Scientific Reports.

[31]  Yuxing Bai,et al.  Aspirin inhibits LPS-induced macrophage activation via the NF-κB pathway , 2017, Scientific Reports.

[32]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[33]  M. Yao,et al.  Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts , 2017, Translational oncology.

[34]  L. Wessels,et al.  Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages , 2017, Oncoimmunology.

[35]  H. Anders,et al.  Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo , 2017, Cytokine.

[36]  D. Hwang,et al.  Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis , 2017, The Journal of clinical investigation.

[37]  M. Chiquet,et al.  Tenascin-C at a glance , 2016, Journal of Cell Science.

[38]  B. Rollins,et al.  CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice , 2016, PloS one.

[39]  A. Kungl,et al.  Interfering with the CCL2–glycosaminoglycan axis as a potential approach to modulate neuroinflammation , 2016, Neuroscience Letters.

[40]  J. Goetz,et al.  Generating and characterizing the mechanical properties of cell-derived matrices using atomic force microscopy. , 2016, Methods.

[41]  M. Heikenwalder,et al.  Targeting of CCL2-CCR2-Glycosaminoglycan Axis Using a CCL2 Decoy Protein Attenuates Metastasis through Inhibition of Tumor Cell Seeding1 , 2016, Neoplasia.

[42]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[43]  T. Handel,et al.  The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization. , 2015, Glycobiology.

[44]  N. Quan,et al.  Immune Cell Isolation from Mouse Femur Bone Marrow. , 2015, Bio-protocol.

[45]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[46]  Jie Wang,et al.  Expression of CCL2 is significantly different in five breast cancer genotypes and predicts patient outcome. , 2015, International journal of clinical and experimental medicine.

[47]  C. Power,et al.  Targeting chemokines: Pathogens can, why can't we? , 2015, Cytokine.

[48]  J. Pollard,et al.  CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages , 2015, The Journal of experimental medicine.

[49]  Maojie Yang,et al.  Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma , 2015, Oncotarget.

[50]  V. Pomin Sulfated glycans in inflammation. , 2015, European journal of medicinal chemistry.

[51]  J. Slotta-Huspenina,et al.  Spatial organization of the tenascin-C microenvironment in experimental and human cancer , 2015, Cell adhesion & migration.

[52]  K. Mertz,et al.  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis , 2014, Nature.

[53]  S. Gordon,et al.  Macrophage heterogeneity in tissues: phenotypic diversity and functions , 2014, Immunological reviews.

[54]  Samia Aci-Sèche,et al.  Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis. , 2014, Cell reports.

[55]  Jorge Joven,et al.  CCL2 Shapes Macrophage Polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-Dependent Gene Expression Profile , 2014, The Journal of Immunology.

[56]  Zhenjie Liu,et al.  Monocyte Chemoattractant Protein-1 (MCP-1) Regulates Macrophage Cytotoxicity in Abdominal Aortic Aneurysm , 2014, PloS one.

[57]  Jeffrey J. Rice,et al.  Tenascin C Promiscuously Binds Growth Factors via Its Fifth Fibronectin Type III-Like Domain , 2013, PloS one.

[58]  K. Pienta,et al.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer , 2013, Investigational New Drugs.

[59]  G. Frühbeck,et al.  Increased tenascin C and Toll-like receptor 4 levels in visceral adipose tissue as a link between inflammation and extracellular matrix remodeling in obesity. , 2012, The Journal of clinical endocrinology and metabolism.

[60]  W. Ye,et al.  CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. , 2012, Cancer research.

[61]  J. Forrester,et al.  Dysregulation in Retinal Para-Inflammation and Age-Related Retinal Degeneration in CCL2 or CCR2 Deficient Mice , 2011, PloS one.

[62]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[63]  Edi Brogi,et al.  Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs , 2011, Nature Medicine.

[64]  Jinghang Zhang,et al.  Abstract 2842: CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011 .

[65]  K. Midwood,et al.  Identification of Novel and Distinct Binding Sites within Tenascin-C for Soluble and Fibrillar Fibronectin♦ , 2011, The Journal of Biological Chemistry.

[66]  S. Singhal,et al.  Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. , 2011, American journal of respiratory cell and molecular biology.

[67]  M. Rossol,et al.  LPS-induced cytokine production in human monocytes and macrophages. , 2011, Critical reviews in immunology.

[68]  Li Yang,et al.  Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. , 2010, Neoplasia.

[69]  G. Wildner,et al.  Rationally Evolving MCP-1/CCL2 into a Decoy Protein with Potent Anti-inflammatory Activity in Vivo* , 2010, The Journal of Biological Chemistry.

[70]  Matthew J. Craig,et al.  CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization* , 2009, The Journal of Biological Chemistry.

[71]  M. Miyazaki,et al.  Stromal MCP‐1 in mammary tumors induces tumor‐associated macrophage infiltration and contributes to tumor progression , 2009, International journal of cancer.

[72]  M. Kashiwagi,et al.  Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease , 2009, Nature Medicine.

[73]  A. Minami,et al.  α9 Integrin and Its Ligands Constitute Critical Joint Microenvironments for Development of Autoimmune Arthritis1 , 2009, The Journal of Immunology.

[74]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[75]  H. Xiong,et al.  Monocyte Chemotactic Protein-1 Regulates Voltage-Gated K+ Channels and Macrophage Transmigration , 2009, Journal of Neuroimmune Pharmacology.

[76]  J. Green,et al.  Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis , 2008, Oncogene.

[77]  M. Miyasaka,et al.  Binding of Lymphoid Chemokines to Collagen IV That Accumulates in the Basal Lamina of High Endothelial Venules: Its Implications in Lymphocyte Trafficking1 , 2007, The Journal of Immunology.

[78]  E. Cukierman,et al.  Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts , 2006, Current protocols in cell biology.

[79]  F. Breedveld,et al.  A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[80]  A. Proudfoot,et al.  The biological relevance of chemokine-proteoglycan interactions. , 2006, Biochemical Society transactions.

[81]  K. Chayama,et al.  Monocyte Chemoattractant Protein-1 Transfection Induces Angiogenesis and Tumorigenesis of Gastric Carcinoma in Nude Mice via Macrophage Recruitment , 2005, Clinical Cancer Research.

[82]  C. Haslett,et al.  Interleukin‐10 inhibits lipopolysaccharide‐induced survival and extracellular signal‐regulated kinase activation in human neutrophils , 2005, European journal of immunology.

[83]  T. Handel,et al.  Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. , 2005, Annual review of biochemistry.

[84]  T. Handel,et al.  Identification of the Glycosaminoglycan Binding Site of the CC Chemokine, MCP-1 , 2004, Journal of Biological Chemistry.

[85]  B. Shalmon,et al.  Progression of mouse mammary tumors: MCP‐1‐TNFα cross‐regulatory pathway and clonal expression of promalignancy and antimalignancy factors , 2003, International journal of cancer.

[86]  Timothy N. C. Wells,et al.  Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Sodhi,et al.  Monocyte chemoattractant protein-1-induced activation of p42/44 MAPK and c-Jun in murine peritoneal macrophages: a potential pathway for macrophage activation. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[88]  A. Doseff,et al.  Monocyte survival factors induce Akt activation and suppress caspase-3. , 2002, American journal of respiratory cell and molecular biology.

[89]  J. Moyano,et al.  Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. , 2001, Cancer research.

[90]  H. Saji,et al.  Significant correlation of monocyte chemoattractant protein‐1 expression with neovascularization and progression of breast carcinoma , 2001, Cancer.

[91]  J. Block,et al.  Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. , 2001, Cell structure and function.

[92]  H. Saji,et al.  Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  J. Ward,et al.  Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. , 2000, Blood.

[94]  B. Torbett,et al.  Presentation of chemokine SDF-1 alpha by fibronectin mediates directed migration of T cells. , 2000, Blood.

[95]  S. Amar,et al.  Differentiation of Monocytes to Macrophages Primes Cells for Lipopolysaccharide Stimulation via Accumulation of Cytoplasmic Nuclear Factor κB , 1999, Infection and Immunity.

[96]  R. Hubbard,et al.  Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. , 1999, Biochemistry.

[97]  C. Power,et al.  Glycosaminoglycans mediate cell surface oligomerization of chemokines. , 1997, Biochemistry.

[98]  E. Spiess,et al.  Tenascin-C contains distinct adhesive, anti-adhesive, and neurite outgrowth promoting sites for neurons , 1996, The Journal of cell biology.

[99]  B. Rollins,et al.  Biochemical and biologic characterization of murine monocyte chemoattractant protein-1. Identification of two functional domains. , 1994, Journal of immunology.

[100]  S. Coughlin,et al.  Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[101]  D. Graves,et al.  Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. , 1992, Journal of immunology.

[102]  K. Matsushima,et al.  Brief Definitive Report Purification and Characterization of a Novel Monocyte Chemotactic and Activating Factor Produced by a Human Myelomonocytic Cell Line , 2022 .

[103]  J. Kuratsu,et al.  Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants , 1989, The Journal of experimental medicine.

[104]  Matthias Chiquet,et al.  Tenascin interferes with fibronectin action , 1988, Cell.